Thermo Fisher expands stem cell program

3 August 2008

US instrument firm Thermo Fisher Scientific has expanded its Thermo Scientific Stem Cell Excellence program, providing new tools and technologies to advance the stem cell research process. The expanded Stem Cell Excellence portfolio now includes Thermo Scientific HyClone AdvanceSTEM reagents, kits and stem cell lines, as well as the Thermo Scientific Dharmacon Accell siRNA reagent for gene silencing and Nunc cell culture inserts for cell-based assays. These products address the needs of researchers conducting stem cell collection and preparation, expansion and differentiation, characterization and analysis, as well as storage and transport.

The recently-launched AdvanceSTEM range of products serves a wide range of stem cell applications and includes HyClone AdvanceSTEM Serum Replacement, to support the growth of undifferentiated embryonic stem cells with minimal or no requirement for fetal bovine serum supplementation; HyClone AdvanceSTEM Low Osmo DMEM, featuring an optimized osmolarity approximating that of murine embryonic tissue; and HyClone AdvanceSTEM ES-Screened Fetal Bovine Serum to aid the rapid growth of ES cells while retaining their pluripotent abilities.

Other HyClone AdvanceSTEM tools include mesenchymal stem cell and amniotic epithelial stem cell expansion kits, osteogenic, adipogenic and neural differentiation kits (developed to support human bone marrow), adipose-derived mesenchymal stem cells as well as multipotent cord blood unrestricted somatic stem cells and mesenchymal stem cells from Wharton's Jelly, and amniotic epithelial stem cells from Cellular Engineering Technologies. Murine embryonic stem cells, B6N and 129/X1 mouse ES cell lines from Primogenix are also available as tools for the modeling of human disease and the understanding of gene function.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight